BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tanaka Y, Yoshida K, Suetsugu T, Imai T, Matsuhashi N, Yamaguchi K. Recent advancements in esophageal cancer treatment in Japan. Ann Gastroenterol Surg 2018;2:253-65. [PMID: 30003188 DOI: 10.1002/ags3.12174] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Kojima T, Hara H, Tsuji A, Yasui H, Muro K, Satoh T, Ogata T, Ishihara R, Goto M, Baba H, Nishina T, Han S, Sakata T, Yatsuzuka N, Doi T, Kato K. First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590. Esophagus. [DOI: 10.1007/s10388-022-00920-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Zhu H, Liu X. Advances of Tumorigenesis, Diagnosis at Early Stage, and Cellular Immunotherapy in Gastrointestinal Malignancies. Front Oncol 2021;11:666340. [PMID: 34434889 DOI: 10.3389/fonc.2021.666340] [Reference Citation Analysis]
3 Chaitin H, Lu ML, Wallace MB, Kang Y. Development of a Decellularized Porcine Esophageal Matrix for Potential Applications in Cancer Modeling. Cells 2021;10:1055. [PMID: 33946915 DOI: 10.3390/cells10051055] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 haghi B, Saghaeian jazi M, zarie M, Khosravi A, tajaldini M, Asadi J; Metabolic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran, Stem cell Research Center, Golestan University of Medical Sciences, Gorgan, Iran, Department of Molecular Medicine, Faculty of Advanced Medical Technologies, Golestan University of Medical Sciences, Gorgan, Iran, Department of Molecular Medicine, Faculty of Advanced Medical Technologies, Golestan University of Medical Sciences, Gorgan, Iran, Ischemic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran, Metabolic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran. Docetaxel Toxicity Optimization in Esophageal Squamous Cell Carcinoma Cell Line YM-1: A Study of Cell Cycle and Doubling Time Effect. mljgoums 2021;15:23-7. [DOI: 10.52547/mlj.15.2.23] [Reference Citation Analysis]
5 Shimada H, Fukagawa T, Haga Y, Okazumi SI, Oba K. Clinical TNM staging for esophageal, gastric, and colorectal cancers in the era of neoadjuvant therapy: A systematic review of the literature. Ann Gastroenterol Surg 2021;5:404-18. [PMID: 34337289 DOI: 10.1002/ags3.12444] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Huang J, Koulaouzidis A, Marlicz W, Lok V, Chu C, Ngai CH, Zhang L, Chen P, Wang S, Yuan J, Lao XQ, Tse SLA, Xu W, Zheng ZJ, Xie SH, Wong MCS. Global Burden, Risk Factors, and Trends of Esophageal Cancer: An Analysis of Cancer Registries from 48 Countries. Cancers (Basel) 2021;13:E141. [PMID: 33466239 DOI: 10.3390/cancers13010141] [Cited by in Crossref: 5] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
7 Yu F, Wang X, Shi H, Jiang M, Xu J, Sun M, Xu Q, Addai FP, Shi H, Gu J, Zhou Y, Liu L. Development of chimeric antigen receptor-modified T cells for the treatment of esophageal cancer. Tumori 2021;107:341-52. [PMID: 32988314 DOI: 10.1177/0300891620960223] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
8 Kakeji Y, Oshikiri T, Takiguchi G, Kanaji S, Matsuda T, Nakamura T, Suzuki S. Multimodality approaches to control esophageal cancer: development of chemoradiotherapy, chemotherapy, and immunotherapy. Esophagus. 2021;18:25-32. [PMID: 32964312 DOI: 10.1007/s10388-020-00782-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
9 Takeda S, Iida M, Kanekiyo S, Nishiyama M, Tokumitsu Y, Shindo Y, Yoshida S, Suzuki N, Yoshino S, Nagano H. Efficacy of intraoperative recurrent laryngeal neuromonitoring during surgery for esophageal cancer. Ann Gastroenterol Surg 2021;5:83-92. [PMID: 33532684 DOI: 10.1002/ags3.12394] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
10 Wada M, Goto Y, Tanaka T, Okada R, Moriya S, Idichi T, Noda M, Sasaki K, Kita Y, Kurahara H, Maemura K, Natsugoe S, Seki N. RNA sequencing-based microRNA expression signature in esophageal squamous cell carcinoma: oncogenic targets by antitumor miR-143-5p and miR-143-3p regulation. J Hum Genet 2020;65:1019-34. [PMID: 32623445 DOI: 10.1038/s10038-020-0795-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
11 Dutta M, Nakagawa H, Kato H, Maejima K, Sasagawa S, Nakano K, Sasaki-Oku A, Fujimoto A, Mateos RN, Patil A, Tanaka H, Miyano S, Yasuda T, Nakai K, Fujita M. Whole genome sequencing analysis identifies recurrent structural alterations in esophageal squamous cell carcinoma. PeerJ 2020;8:e9294. [PMID: 32617189 DOI: 10.7717/peerj.9294] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
12 Hempel D, Wieland T, Solfrank B, Grossmann V, Steinhard J, Frick A, Hempel L, Eberl T, Gaumann A. Antitumor Activity of Larotrectinib in Esophageal Carcinoma with NTRK Gene Amplification. Oncologist 2020;25:e881-6. [PMID: 32323889 DOI: 10.1634/theoncologist.2019-0641] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
13 Nishida N, Yamsaki M, Odagiri K, Yamashita K, Tanaka K, Sakai D, Makino T, Takahashi T, Kurokawa Y, Satoh T, Mori M, Doki Y. Combination Therapy With S-1, Oxaliplatin and Leucovorin in Patients With Advanced Esophageal Squamous Cell Carcinoma. In Vivo 2019;33:2249-54. [PMID: 31662564 DOI: 10.21873/invivo.11730] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
14 Takeda FR, Tustumi F, Nigro BC, Sallum RAA, Ribeiro-Junior U, Cecconello I. TRANSHIATAL ESOPHAGECTOMY IS NOT ASSOCIATED WITH POOR QUALITY LYMPHADENECTOMY. Arq Bras Cir Dig 2019;32:e1475. [PMID: 31859928 DOI: 10.1590/0102-672020190001e1475] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
15 Škrlová K, Malachová K, Muñoz-Bonilla A, Měřinská D, Rybková Z, Fernández-García M, Plachá D. Biocompatible Polymer Materials with Antimicrobial Properties for Preparation of Stents. Nanomaterials (Basel) 2019;9:E1548. [PMID: 31683612 DOI: 10.3390/nano9111548] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
16 Douzandegan Y, Tahamtan A, Gray Z, Nikoo HR, Tabarraei A, Moradi A. Cell Death Mechanisms in Esophageal Squamous Cell Carcinoma Induced by Vesicular Stomatitis Virus Matrix Protein. Osong Public Health Res Perspect 2019;10:246-52. [PMID: 31497497 DOI: 10.24171/j.phrp.2019.10.4.08] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
17 Ueki N, Akazawa Y, Miura S, Matsuda K, Kurohama H, Imaizumi T, Kondo H, Nakashima M. Significant association between 53 BP1 expression and grade of intraepithelial neoplasia of esophagus: Alteration during esophageal carcinogenesis. Pathol Res Pract 2019;215:152601. [PMID: 31570283 DOI: 10.1016/j.prp.2019.152601] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
18 Zhang R, Zou J, Li P, Li Q, Qiao Y, Han J, Huang K, Ruan P, Lin H, Song Q, Fu Z. Surgery to the primary tumor is associated with improved survival of patients with metastatic esophageal cancer: propensity score-matched analyses of a large retrospective cohort. Diseases of the Esophagus 2019. [DOI: 10.1093/dote/doz051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
19 Moaven O, Wang TN. Combined Modality Therapy for Management of Esophageal Cancer: Current Approach Based on Experiences from East and West. Surg Clin North Am 2019;99:479-99. [PMID: 31047037 DOI: 10.1016/j.suc.2019.02.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
20 Nakanishi K, Daiko H, Kato F, Kanamori J, Igaki H, Tachimori Y, Koyanagi K. Efficacy of preserving the residual stomach in esophageal cancer patients with previous gastrectomy. Gen Thorac Cardiovasc Surg 2019;67:470-8. [PMID: 30778905 DOI: 10.1007/s11748-019-01070-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Lin M, Firoozi N, Tsai CT, Wallace MB, Kang Y. 3D-printed flexible polymer stents for potential applications in inoperable esophageal malignancies. Acta Biomater 2019;83:119-29. [PMID: 30366130 DOI: 10.1016/j.actbio.2018.10.035] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 13.0] [Reference Citation Analysis]
22 Ueda H, Kawakami H, Nonagase Y, Takegawa N, Okuno T, Takahama T, Takeda M, Chiba Y, Tamura T, Nakagawa K. Phase II Trial of 5-Fluorouracil, Docetaxel, and Nedaplatin (UDON) Combination Therapy for Recurrent or Metastatic Esophageal Cancer. Oncologist 2019;24:163-e76. [PMID: 30361422 DOI: 10.1634/theoncologist.2018-0653] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]